FILTER
LATEST INTERVIEWS
Gonzalo Covarrubias
GENERAL MANAGER, WSP PERU
"Large projects are a multidisciplinary challenge, and their development must include all the stakeholders; these groups cannot work in silos. Furthermore, how we exploit resources and develop future mining operations must consider climate change, wealth-creation for communities, and evolving technologies."
Helio Coelho
GLOBAL CHEMICAL SALES DIRECTOR – LATIN AMERICA, BDP INTERNATIONAL
BDP International discusses how innovation and technology can overcome logistical bottlenecks.
Peter J. Cashin
PRESIDENT & CEO, IMPERIAL MINING GROUP LTD
Imperial Mining speaks about developing its strategic rare earth asset in Québec.
Massimo Scaccabarozzi
PRESIDENT, FARMINDUSTRIA
Farmindustria speaks to GBR about the importance of pharmaceuticals to the Italian economy and society.
Shankar Musunuri
CHAIRMAN, CEO & CO-FOUNDER, OCUGEN
Ocugen explains its work on cures for unmet needs in the ophthalmology space and COVID-19 vaccine development.
Massimiliano Rocchi
SENIOR DIRECTOR ITALY AND GREECE, ACCORD HEALTHCARE ITALIA
Accord Healthcare Italia explains the challenges and opportunities for generics producers in Italy.
Luca Crippa
CEO & MANAGING DIRECTOR, IBSA FARMACEUTICI
Instituto Biochimico, with 2,000 global employees, is attempting to take generics to the next level and continue to expand around the world.
Franco Lori
CEO & FOUNDER, VIROSTATICS
Virostatics is a private drug discovery and development company focused on NCEs used in the treatment of cancers and viral diseases.
Lehlohonolo Amos Molloyi
CEO, MINING EQUIPMENT MANUFACTURERS OF SOUTH AFRICA (MEMSA)
MEMSA explains how it is supporting national mining equipment manufacturers in South Africa.
Murray Hill
MANAGING DIRECTOR & CEO, ELEVATE URANIUM
Elevate Uranium holds the largest tenement position for nuclear fuel minerals (uranium) in Namibia and explains its U-pgrade beneficiation process.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
